Evidence map›Paper›PMID 29638042›Full record

ArticleMolecular oncology2018

Microfluidic enrichment of plasma cells improves treatment of multiple myeloma.

Yunjing Zeng, Li Gao, Xiaoqing Luo, Yan Chen, Mustafa H Kabeer, Xuelian Chen, Andres Stucky, William G Loudon, Shengwen C Li, Xi Zhang and 1 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Yunjing ZengDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
Li GaoDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
Xiaoqing LuoDepartment of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Yan ChenShenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Beijing, China.
Mustafa H KabeerChildren's Hospital of Orange County, University of California-Irvine School of Medicine, Orange, CA, USA.
Xuelian ChenDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
Andres StuckyDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
William G LoudonChildren's Hospital of Orange County, University of California-Irvine School of Medicine, Orange, CA, USA.
Shengwen C LiDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
Xi ZhangDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
Jiang F ZhongDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
University of Southern California · USUniversity of California, Irvine · USXinqiao Hospital · CNChinese Academy of Sciences · CN

Funding

Multi-phase Microfluidic Devices for Characterization of Circulating Tumor CellsR01CA164509 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHONG, JOHN · 2012 to 2016
$2.0M
Molecular Characteristics of Treatment-resistant High-risk NeuroblastomaR01CA197903 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHONG, JOHN · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA164509NCI NIH HHS R01 CA197903
6 · The paper itself

Abstract

Cytogenetic alterations form the basis for risk stratification for multiple myeloma (MM) and guide the selection of therapy; however, current pathology assays performed on bone marrow samples can produce false-negatives due to the unpredictable distribution and rarity of MM cells. Here, we report on a microfluidic device used to facilitate CD45 depletion to enhance the detection of cytogenetic alterations in plasma cells (PCs). Bone marrow samples from 48 patients with MM were each divided into two aliquots. One aliquot was subjected to classic flow cytometry and fluorescent in situ hybridization (FISH). The other first went through CD45

Indexed as

AdultAgedCell Line, TumorFemaleHumansLeukocyte Common AntigensMaleMicrofluidicsMiddle AgedMultiple MyelomaPlasma CellsRisk AssessmentTreatment OutcomeLeukocyte Common Antigensmicrofluidicmyelomarisk stratification

Identifiers

PMID29638042
PMCPMC6026869
OpenAlexW2798098622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.